篇名

藥品智財、管制與衛生治理   免費試閱

並列篇名

Intellectual Property, Drug Regulatory, and Health Governance

中文摘要

在全球衛生治理的戰場上,藥品與醫療器材無疑是最重要的武器之一,在嚴重特殊傳染性肺炎(COVID-19)疫情肆虐全球的當下,更是如此。然而該類醫藥產品與生技產業,因開發週期長、成本大、風險高的特性,亟需一個以國家高權力量為後盾的法律制度,來為其提供資源、控管風險與保護利益。就此,本文以藥品為例,分別從專利及管制的兩個面向,以臺灣法律的背景來探討其對衛生治理的意義。

英文摘要

During the current global COVID-19 pandemic, drugs and medical devices have again shown how they can be a critical weapon in the battlefield of health governance. However, due to the inherent characters of a longdeveloping period, high costs, and unexpected risks, the products and biotechnology industry need a comprehensive regime supported by state sovereignties to provide sufficient resources, control unpredictable risks, and protect their interests. This paper uses drugs as an example and Taiwan laws as the background to discuss how the products play a critical role in health governance from intellectual property and regulatory perspectives.

起訖頁

097-109

出版單位
DOI

10.3966/241553062021050055008  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP